➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
McKesson
Johnson and Johnson
Merck
Baxter

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Claims for Patent: 5,605,690

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 5,605,690
Title: Methods of lowering active TNF-.alpha. levels in mammals using tumor necrosis factor receptor
Abstract:A method for treating TNF-dependent inflammatory diseases in a mammal by administering a TNF antagonist, such as soluble TNFR.
Inventor(s): Jacobs; Cindy A. (Seattle, WA), Smith; Craig A. (Seattle, WA)
Assignee: Immunex Corporation (Seattle, WA)
Application Number:08/385,229
Patent Claims:1. A method for lowering the levels of active TNF-.alpha. in a mammal in need thereof which comprises administering to said mammal a TNF-lowering amount of a TNF antagonist selected from the group consisting of:

(a) a TNF receptor comprising the sequence of amino acids 3-163 of SEQ ID NO:1; and

(b) a chimeric antibody comprising a TNF receptor according to (a) fused to the constant domain of an immunoglobulin molecule.

2. A method for lowering the levels of active TNF-.alpha. in a mammal in need thereof which comprises administering to said mammal a TNF-lowering amount of a TNF receptor comprising the sequence of amino acids 3-163 of SEQ ID NO:1.

3. A method for lowering the levels of active TNF-.alpha. in a mammal in need thereof which comprises administering to said mammal a TNF-lowering amount of a chimeric antibody comprising a TNF receptor comprising the sequence of amino acids 3-163 of SEQ ID NO:1 fused to the constant domain of an immunoglobulin molecule.

4. A method for lowering the levels of active TNF-.alpha. in a mammal having arthritis, which comprises administering to such mammal a therapeutically effective amount of a TNF-antagonist selected from the group consisting of:

(a) a TNF receptor comprising the sequence of amino acids 3-163 of SEQ ID NO:1; and

(b) a chimeric antibody comprising a TNF receptor according to (a) fused to the constant domain of an immunogloblin molecule.

5. A method for lowering the levels of active TNF-.alpha. in a mammal having arthritis, which comprises administering to said mammal a TNF-lowering amount of a TNF receptor comprising the sequence of amino acids 3-163 of SEQ ID NO:1.

6. A method for lowering the levels of active TNF-.alpha. in a mammal having arthritis, which comprises administering to said mammal a TNF-lowering amount of a chimeric antibody comprising a TNF receptor comprising the sequence of amino acids 3-163 of SEQ ID NO:1 fused to the constant domain of an immunoglobulin molecule.

Details for Patent 5,605,690

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02 ⤷  Free Forever Trial Immunex Corporation (Seattle, WA) 2014-02-25 RX Orphan company
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02 ⤷  Free Forever Trial Immunex Corporation (Seattle, WA) 2014-02-25 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Dow
Harvard Business School
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.